Stiefel Laboratories, Biopharm Services, Multisorb Technologies, the Pharmaceutical Research and Manufacturers of America, Catalent Pharma Solutions and Chromatide have all had people on the move in the world of pharmaceutical manufacturing.
Miriam Monge has been appointed as vice president of marketing & disposables systems implementation at BioPharm Services (BPS).
For the past 14 years Monge worked as marketing director of Stedim Biosystems where she worked on building Stedim's disposable fluid handling business in the bioprocessing industry in Europe. In her new role she will lead BPS's Disposables Implementation practice, providing support for all aspects of the implementation of disposable manufacturing systems.
Laurent Rozier has been appointed the role of Multisorb Technologies business development representative, healthcare packaging for central and southern Europe.
Rozier has gained nearly 10 years' experience with packaging technology and formulation chemistry and has a successful sales history with healthcare product manufacturers and packagers in Europe.
Richard T Clark, chief executive officer and president of Merck, has been elected board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA).
Clark has been chairman of Merck's board of directors since April 2007 and has been the company's CEO and president since May 2005. Prior to this he was president of the Merck Manufacturing Division from 2003 to 2005.
Also elected were AstraZeneca CEO David Brennan as chairman-elect of the PhRMA board of directors and Pfizer chairman and CEO Jeffrey Kindler as board treasurer.
Matthew Walsh has been appointed as senior vice president, finance and chief financial officer of Catalent Pharma Solutions.
Walsh has extensive public company financial leadership experience, most recently as president and chief financial officer of Escala Group. He previously worked at diversified industrial manufacturer GenTek for ten years, where he was appointed as vice president and chief financial officer.
Clare Hildred has been appointed as the new chief executive officer of Chromatide, an IP-driven company providing specialised synthesis and purification products and services.
Her previous position was as finance and business improvement director at Avecia Biotechnology where she was involved in major contract negotiations. Hildred has over 17 years' post qualification experience in high value business management.
Cortegra, a contract manufacturer of pharmaceutical labeling and packaging products, has appointed Jill Case Harper as the company's first human resources manager. She previously worked as the human resources generalist at Red Spot Paint & Varnish Company.
UK-based Fulcrum Pharma has appointed Frank Armstrong as its new CEO where he will work closely with the current CEO Jon Court who has taken the role of director of strategic business development.
Armstrong has previously been CEO of CuraGen, Bioaccelerate Holdings, Provensis and Phoqus Pharmaceuticals. He has 20 years of experience at bringing products to the market in the pharmaceutical and biotechnology industries.
Gregory Tibbitts has been appointed to the board of directors of IDM Pharma, a US-based company focused on anti-cancer drugs.
Tibbitts is currently the chief financial officer for CryoCor and has over 19 years of experience in the financial and pharmaceutical industries. This includes senior positions in a number of companies, such as chief financial officer at Elitra Pharmaceuticals, a privately-held drug discovery company.
Nucleonics, a US-based privately held biotechnology company focused on the development of novel RNAi-based therapeutics, has appointed Michael Young as chief medical officer.
Young was previously president and managing consultant of MDY-Associates, a group of independent experts who provide strategic and technical input to health care endeavors at critical points in their development. Prior this he spent 27 years within the pharmaceutical industry at companies including Proctor & Gamble and Medeva.
Stiefel Laboratories, an independent US-based pharmaceutical company specialising in dermatology, has appointed Gavin Corcoran the newly created position of chief scientific officer.
Corcoran has been promoted from his role as senior vice president, global research and development at Stiefel. He has previously worked at top drug industry companies including Bayer, Schering-Plough and Amgen and has been given the brief of strengthening the collaboration between Stiefel's five R&D facilities.
Mark Bagnall has been appointed as executive vice president and chief financial officer of US-based Adventrx Pharmaceutcials, a company focused on development of antiviral and anticancer technologies.
The position of executive vice president has been newly created and entails working with the CEO and president to define the company's long term strategy. Mr Bagnall has held senior management positions in the biotechnology industry for the past 20 years, including a role on Adventrx's board of directors, which he will remain on after staring his new post.
US-based Alba Therapeutics, a biopharmaceutical company focused on modulation of cellular tight junctions to treat inflammatory and autoimmune diseases, has appointed Bruce Peacock as its CEO.
Peacock has previously worked in senior management positions at companies such as Cephalon, Centocor and Orthovita and Alba believe this his appointment will bring further developmental and financial success to the company.
Mary Fisher has been appointed as the new CEO of SkinMedica, a US-based pharmaceutical company specialising in dermatological treatments.
Ms Fisher was most recently CEO at Acorda Therapeutics, where she spent seven years in a variety of posts. Prior to this she worked for 18 years in the pharmaceutical and biotechnology sectors for companies including Cephalon, Immunex and Boehringer Ingelheim.